Blood sugar is the last thing to change. Long before glucose or HbA1c moves, the body is working harder to keep them normal — and fasting insulin is the test that measures that effort.
It is the earliest widely available signal of a process that ends in type 2 diabetes, and it is almost never included in routine blood work.
Reviewed by Dr. David Oliak, board-certified surgeon
Updated August 2026
When you eat, glucose enters your bloodstream. Insulin is the signal that tells cells to take it up — muscle to use or store it, liver to store it, fat tissue to store it. Blood sugar comes back down, and insulin falls back to a baseline.
Insulin resistance means those cells respond less readily to that signal. The same amount of insulin moves less glucose.
The body's response is straightforward: make more insulin. And it works. Enough extra insulin will move the glucose, and blood sugar stays exactly where it should be.
That is the part worth understanding. The system does not fail early — **it compensates**, quietly and effectively. And a standard blood test cannot tell the difference between a body that is fine and a body that is working hard to look fine.
Because compensation works, glucose is a late signal.
The sequence runs in one direction. Cells become resistant. Insulin rises to compensate. Glucose stays normal. Insulin rises further. Glucose still stays normal — until the pancreas can no longer produce enough to keep up, at which point glucose finally begins to drift upward.
That drift is what gets labelled prediabetes, and then type 2 diabetes.
By the time the label arrives, the process has been running for a long time and the pancreas has already lost some of its capacity to compensate.
Fasting insulin measures the compensation itself — the part that happens first and lasts longest. That is the whole argument for the test.
The first two stages are where the process is most reversible, and they are the two a standard panel cannot see.
Routine blood work is built to detect and monitor diabetes, and it does that well. The diagnostic criteria for diabetes are based on glucose and HbA1c, so those are what get measured. Insulin is not part of the diagnosis, so it is not part of the screen.
That is a reasonable design for the question routine screening is asking. It is simply a different question from the one this test answers.
A comprehensive panel measures fasting insulin because the useful moment is earlier — while the trajectory is still easy to change. And it is earlier while nothing has yet met the definition of a disease.
For most of my career I thought in terms of treating disease that had arrived, which is what medical training teaches. Weight-loss surgery is a remarkably effective version of that — it improves not just weight but metabolic disease, inflammation, joints, how people feel every day.
What changed my thinking was the set point. Once weight is gained the body defends it, and losing it is far harder than never having gained it. Metabolic disease behaves the same way: established, you manage it; early, you can still change where it is going.
— Dr. David Oliak, board-certified physician and surgeon
Reference ranges for fasting insulin are wide, they differ between laboratories, and they were built from population averages rather than from what is optimal.
A result inside the range is not automatically reassuring. And a result near the top of it in someone with abdominal weight gain and a family history means something different from the same result in someone without.
This is why we do not publish a target number. The value is read against your glucose, your lipids, your weight history, your family history, and how you feel.
HOMA-IR is a simple calculation combining fasting insulin and fasting glucose into a single index of insulin resistance. It is useful, and it is still a number that needs interpreting rather than a verdict.
The trend matters more than any single reading. A fasting insulin that has risen across two years is more informative than one measurement, which is one of the arguments for establishing a baseline before anything is wrong.
Insulin resistance rarely appears alone, and several of the markers it travels with are on the same panel.
Triglycerides rise and HDL falls, often before anything else on a lipid panel looks unusual. The ratio between them is a useful signal in its own right.
Liver markers drift. ALT and GGT commonly rise with fat accumulation in the liver, which tracks closely with insulin resistance and which produces no symptoms of its own for a very long time.
Uric acid rises. Blood pressure often creeps up. Weight settles around the abdomen rather than distributing as it once did.
Individually, each of these is easy to explain away. Together, and read alongside a rising fasting insulin, they describe one process rather than five unrelated findings.
For most people, early insulin resistance produces no symptoms at all. That is the reason it is found on testing rather than in the consulting room.
Where there are signs, they are non-specific and easy to attribute elsewhere: fatigue after meals, difficulty losing weight despite genuine effort, weight settling at the waist, increased hunger or cravings for carbohydrate.
Occasionally there are physical signs — skin tags, or darkened velvety patches of skin at the neck or armpits, which is called acanthosis nigricans and is worth mentioning to a clinician.
None of these is diagnostic, and their absence means nothing either way.
This is the part that makes the test worth running: early insulin resistance is among the more reversible findings in medicine.
Muscle is the largest destination for glucose in the body, and resistance training improves how readily it takes glucose up. This is the single most underrated intervention here, and it works independently of weight change.
Reducing refined carbohydrate and added sugar lowers the demand for insulin directly.
Weight loss improves insulin sensitivity substantially, and modest weight loss produces disproportionate improvement — the first several percent does more than the rest.
Sleep matters more than most people expect; short or disrupted sleep worsens insulin sensitivity measurably within days.
And where medication is appropriate, it is available. What is right depends on the whole picture, which is what the evaluation establishes.
The reason to find this early is not that it is dangerous today. It is that the same finding, ten years later, is a longer and less complete recovery.
Let's begin
Fasting insulin is part of the comprehensive panel, read alongside your glucose, lipids, liver and inflammatory markers. And it is interpreted with you in an unhurried hour rather than handed over as a number. In Brea. To speak with us first, call 714-671-2005.
What a comprehensive blood panel measures
ApoB and Lp(a): better measures of cardiovascular risk
"Normal" versus optimal
Why your body defends its weight: the set point
A blood test measuring how much insulin your body is producing in the fasted state. Because insulin's job is to keep blood sugar normal, the amount you need is a measure of how readily your cells are responding to it. More insulin for the same result means the cells are responding less.
Routine panels are designed to detect and monitor diabetes, and the diagnostic criteria for diabetes are based on glucose and HbA1c. Insulin is not part of the diagnosis, so it is not part of the screen. It answers a different question — not "is there disease" but "is the process underway."
Reference ranges are wide, vary between laboratories, and are drawn from population averages rather than from what is ideal. We do not publish a target, because the number means different things depending on your glucose, lipids, weight history and family history.
It is read in context, and the trend over time tells you more than any single value.
Yes, and that is the usual situation. Normal glucose means the compensation is working, not that nothing is happening. Glucose is the last marker to change.
A calculation that combines fasting insulin and fasting glucose into a single index of insulin resistance. It is a useful summary and still needs interpreting alongside everything else.
No. Prediabetes is defined by glucose and HbA1c crossing specific thresholds. Insulin resistance is the process that leads there, and it is measurable well before those thresholds are met.
Early, it is among the more reversible findings in medicine. That is through resistance training, reduced refined carbohydrate, weight loss, and sleep, with medication where appropriate. It becomes harder to reverse the longer it runs, which is the argument for looking early.
Yes. It must be a fasting morning draw, alongside fasting glucose, or the result cannot be interpreted.
